# US 2023/0272431 A1 · Methods and compositions for editing the b2m locus in b cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272431 A1
- Document ID: US20230272431A1
- Status: Published application
- Kind: A1
- Application number: 18/012,031
- Filed: 2021-06-30
- Published: 2023-08-31
- Earliest claimed: 2020-07-03
- Assignees: Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Applicants: Seattle Children's Hospital (Dba Seattle Children's Research Institute)
- Inventors: David J. Rawlings; Richard G. James; Claire Marie Stoffers; Peter J. Cook
- Web page: https://patentgrep.com/patent/US20230272431A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/907: {in mammalian cells}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 5/0635: {B lymphocytes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2510/00: Genetically modified cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Some embodiments of the methods and compositions provided herein include preparing modified B cells. In some embodiments, an endogenous beta-2 microglobulin (B2M) gene in a B cell is modified. Some embodiments relate to increasing the resistance of modified B cells to killing by allogeneic immune cells. In some embodiments, the endogenous B2M gene is inactivated increasing the resistance of the modified B cell to killing by allogeneic immune cells. In some embodiments, a replacement MHC-I is inserted into an inactivated endogenous B2M gene increasing the resistance of the modified B cell to killing by allogeneic immune cells. Some embodiments include enriching for successfully modified cells.

## Claims

### Claim 1

A system for modifying an endogenous beta-2 microglobulin (B2M) gene in a cell, comprising:
a nuclease capable of cleaving a targeted locus in an endogenous B2M gene in a genome of the cell, or a nucleic acid encoding the nuclease; and optionally:
a guide RNA (gRNA) comprising a sequence complementary to the B2M gene, and/or
a repair template comprising a first homology arm, a second homology arm, and a nucleic acid encoding a payload therebetween, wherein the first homology arm and/or the second homology arm has homology to a sequence in the B2M gene.

### Claim at position 2

2-77. (canceled)
